Literature DB >> 3155777

Studies on the binding of C3b-coated microspheres to human neutrophils.

J D Ogle, C K Ogle, J G Noel, P Hurtubise, J W Alexander.   

Abstract

A method is described for the quantitation of C3b receptors on human neutrophils using a mixture of C3b-coated fluorescent and C3b-coated non-fluorescent microspheres. The method measures the "sterically available' C3b receptors on the cells, for example, the receptors available to opsonized bacteria. The use of mixtures of fluorescent and non-fluorescent microspheres resulted in lowered fluorescence intensities of the microsphere-coated neutrophils that were well within the fluorescence limitations of fluorescence activated cell analyzers or sorters used in the assay procedure. These mixtures also allowed the distribution of the C3b-coated microspheres around the neutrophils to be easily visualized in the fluorescence microscope. The binding of the C3b-coated microspheres to the neutrophils was shown to be receptor mediated by typical saturable binding kinetics, by complete inhibition by fluid phase C3b, but not by other proteins and by nearly complete inhibition by anti-C3b receptor antibody. Several parameters that could affect the binding of C3b-coated microspheres to neutrophils were studied; these included time and temperature of incubation of the microspheres with the cells, the diameter of the microspheres, the C3b content of the C3b-coated microspheres, the presence of metal ions, azide, EDTA, protein (BSA, IgG), soybean trypsin inhibitor in the buffers, and the method of isolation of the neutrophils. The C3b-coated microspheres were evenly distributed around the neutrophils in almost all of the cases; however, the neutrophils used in these studies were not activated and were not phagocytosing. The method is extremely reproducible and sensitive in detecting small changes in number of C3b receptors on cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3155777     DOI: 10.1016/0022-1759(85)90480-6

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Rapid whole-blood microassay using flow cytometry for measuring neutrophil phagocytosis.

Authors:  C White-Owen; J W Alexander; R M Sramkoski; G F Babcock
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

2.  Characterization of rapidly adhering amniotic fluid cells by combined immunofluorescence and phagocytosis assays.

Authors:  K Polgár; R Adány; G Abel; J Kappelmayer; L Muszbek; Z Papp
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

3.  Tumour necrosis factor triggers granulocytes to internalize complement-coated virus particles.

Authors:  J A van Strijp; M E van der Tol; L A Miltenburg; K P van Kessel; J Verhoef
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

4.  Effects of chemotactic peptide f-Met-Leu-Phe (FMLP) on C3b receptor (CR1) expression and phagocytosis of microspheres by human neutrophils.

Authors:  J D Ogle; J G Noel; R M Sramkoski; C K Ogle; J W Alexander
Journal:  Inflammation       Date:  1990-06       Impact factor: 4.092

5.  Complement-mediated phagocytosis of herpes simplex virus by granulocytes. Binding or ingestion.

Authors:  J A Van Strijp; K P Van Kessel; M E van der Tol; J Verhoef
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

6.  Comparison of abilities of recombinant interleukin-1 alpha and -beta and noninflammatory IL-1 beta fragment 163-171 to upregulate C3b receptors (CR1) on human neutrophils and to enhance their phagocytic capacity.

Authors:  J D Ogle; J G Noel; A Balasurbramaniam; R M Sramkoski; C K Ogle; J W Alexander
Journal:  Inflammation       Date:  1990-04       Impact factor: 4.092

7.  Effects of combination of tumor necrosis factor alpha and chemotactic peptide, f-Met-Leu-Phe, on phagocytosis of opsonized microspheres by human neutrophils.

Authors:  J D Ogle; J G Noel; R M Sramkoski; C K Ogle; J W Alexander
Journal:  Inflammation       Date:  1992-02       Impact factor: 4.092

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.